site logo

Eisai, Biogen to test FDA by asking for approval of second Alzheimer's drug

The Japanese pharma and Biogen partner is filing an application for accelerated OK of lecanemab, which works similarly to the companies' controversially cleared Aduhelm.

Getty Images